1. Renal damage occurs in 1 out of 4 hypertensives Adapted from Leoncini et al. J Hypertens. 2008;26:427-432.

2. Optimal protection should reduce the risk of death Adapted from Dzau et al. Circulation. 2006;114;2850-2870.

3. ADVANCE: renal protection that translates into mortality reduction * Versus patients, 73% of whom were receiving an ACE inhibitor or a sartan. ** Development of macroalbuminuria, doubling of serum creatinine to a level of at least 2.26 mg/dL (200 mol/L), need for renal replacement therapy or death due to renal disease. *** All-cause mortality. 1. De Galan et al. J Am Soc Nephrol. 2009;20:883-892. 2. Lambers Heerspink et al; ADVANCE Collaborative Group. Eur Heart J. 2010;31:2888-2896. 3. Patel et al; ADVANCE Collaborative Group. Lancet. 2007;370:829-840.

4. Kidney protection translating into mortality reduction More extensive assessment is available in García-Donaire et al. Blood Press. 2011;20:322–334. *renal events, **urinary albumin/creatinine ratio; †urinary albumin excretion rate, ‡doubling serum creatinine. RRR = relative risk reduction; NS = not significant. Results should be interpreted line by line, in comparison with a control group specific to the trial.